Key facts
- CUTISS’s last known valuation is $214.5M (Sep 2025).
- It has raised $139.5M; the latest was Later Stage VC ($69.7M) in Sep 2025.
- Notable investors include Innosuisse, Zürcher Kantonalbank, Venture (Switzerland), GG 1978, ETH Zürich Foundation — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for CUTISS
- ·The full record, as it builds
Funding rounds
No funding rounds for CUTISS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CUTISS
Developer of customized bio-engineered skin grafts designed to treat large skin defects. The company's customized skin grafts use patients' cells in combination with a hydrogel to create dermo-epidermal skin and considerably reduce the need for autografting and further corrective interventions, allowing for considerable savings, enabling patients to get treated for affected or damaged skin.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2015
- Employees
- 50
- Website
- cutiss.swiss/
- Ownership
- Privately Held (backing)
CUTISS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CUTISS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CUTISS in its N-PORT filings yet. We sweep new filings monthly.